Artal Group S.A. Clovis Oncology, Inc. Transaction History

Artal Group S.A.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 13, 2020	BUY	$3.0 - $16.43 $1.5 Million - $8.22 Million	500,000 Added 100.0%	1,000,000 $10.4 Million
Q3 2019 Nov 14, 2019	BUY	$3.93 - $15.35 $1.57 Million - $6.14 Million	400,000 Added 400.0%	500,000 $1.97 Million
Q4 2017 Feb 09, 2018	SELL	$57.69 - $84.58 $865,350 - $1.27 Million	-15,000 Reduced 13.04%	100,000 $6.8 Million
Q3 2017 Nov 08, 2017	BUY	$67.17 - $84.81 $7.72 Million - $9.75 Million	115,000	115,000 $9.48 Million

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

Stay updated on Artal Group S.A. with notifications on news.